Ian Swan

Associate

Contact

Practice Areas

Intellectual Property

Ian Swan is an associate in Axinn’s Intellectual Property group. His practice focuses on pharmaceutical and biotechnology-related patent litigation.

Ian Swan

Associate

Washington, DC

Contact

Practice Areas

Intellectual Property

Download PDF Download V-Card

Ian Swan is an associate in Axinn’s Intellectual Property group. His practice focuses on pharmaceutical and biotechnology-related patent litigation.

Ian earned his JD from Boston College Law School. While in law school, he interned at the Essex County District Attorney's Office and also for the U.S. District Court for the District of Massachusetts.

Ian was a summer associate with Axinn in 2022 and holds a BS in Biology from the University of Massachusetts, Amherst.

^{Not yet admitted to the Washington, DC, Bar.}

Education

JD – Boston College Law School (2023)
BS, Biology – University of Massachusetts, Amherst (2019)

Admissions

Maryland

Quotes

Top to bottom, the Axinn team has excellent lawyers.

The Legal 500 United States

Profile

Education

Admissions

Top to bottom, the Axinn team has excellent lawyers.

The Legal 500 United States

Top to bottom, the Axinn team has excellent lawyers.

The Legal 500 United States

News & Insights

View all Insights

November 13, 2024

ITCTLA Mock Hearing Program 2024

On November 13, Axinn associates Ramya Auroprem and Ian Swan* will participate in the International Trade Commission Trial Lawyers Association’s Mock Hearing Program in Washington, DC.

Speaking Engagement

Intellectual Property

June 28, 2024

The Floodgates Have Opened: Supreme Court Scuttles Chevron, Brings New Uncertainty to Regulated Industries

For forty years, Chevron has put a thumb on the scales in favor of the executive agencies whenever their decisions were challenged in...

Axinn Viewpoints

Intellectual Property

June 13, 2024

Hatch-Waxman Overview

The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, forms the current framework for the United States’ regulation of drug approvals. The law amended the Food, Drug, and Cosmetic Act of 1938 (FDCA) in an effort to streamline the approval process for generic drugs while preserving incentives to innovate. Given the Hatch-Waxman Act's significance in the United States’ regulatory and patent systems, it is important to understand its structure and contours.

Byline Articles

Intellectual Property

News & Insights

Related People

Thomas K. Hedemann

Counsel

Thomas Hedemann focuses his practice on intellectual property and commercial litigation. His experience ranges across all aspects of litigation from pre-litigation counseling and strategy through fact and expert discovery, dispositive motions and trial. Thomas also has significant appellate experience before the Federal and Second Circuit Courts of Appeals.

Learn more

Matthew J. Becker

Intellectual Property Practice Chair

Matt Becker is the Chair of the Intellectual Property practice and has over 25 years of experience trying and litigating a diverse range of patent infringement and trade secret cases. He has tried numerous high-stakes cases to both courts and juries.

Learn more

Ted Mathias

Partner

Ted Mathias serves as lead counsel in complex patent litigation, often managing cases involving more than 15 patents. He frequently handles matters at the intersection of patent and antitrust law, with a strong focus on advising clients in the pharmaceutical industry.

Learn more

Matthew S. Murphy

Partner

Matt Murphy leverages his prior experience as a research scientist to represent pharmaceutical, life sciences, and other companies in complex patent and trade secret litigation.

Learn more